Liposomal Daunorubicin + Cytarabine: Enhanced Synergistic Antineoplastic Effect in AML Treatment
Interview: There is a critical need for more effective therapies, as current treatment strategies still fall short of achieving long-term disease control in a substantial proportion of patients.
In this interview, Dr. Andrea Lenartova, senior hematologist at Oslo University Hospital and specialist in AML, shares her insights into the newly approved therapy.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
